

# HYPERFINE

## Hyperfine, Inc. to Present at the Oppenheimer 34th Annual Healthcare Conference

February 28, 2024

GUILFORD, Conn.--(BUSINESS WIRE)--Feb. 28, 2024-- [Hyperfine, Inc.](https://www.businesswire.com/news/home/20240228281785/en/) (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world's first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system, today announced plans to present at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference, taking place virtually. Members of management are scheduled to present on Wednesday, March 13, 2024, at 2:40 pm ET.

A live webcast of the event, as well as an archived recording will be available on the “Investors” section of the company’s website at: [investors.hyperfine.io](https://investors.hyperfine.io). The webcasts will be archived and available for replay for at least 90 days after the event.

For more information about the *Swoop® Portable MR Imaging®* system, please visit [hyperfine.io](https://hyperfine.io).

### **About Hyperfine, Inc. and the Swoop® Portable MR Imaging® System**

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020 as a portable magnetic resonance brain imaging device for producing images that display the internal structure of the head where a full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system has been approved for brain imaging in several countries, including Canada and Australia, has UKCA certification in the United Kingdom, CE certification in the European Union, and is also available in New Zealand.

The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. Traditionally, access to costly, stationary, conventional MRI technology can be inconvenient or not available when needed most. With the portable, ultra-low-field Swoop® system, Hyperfine, Inc. is redefining the neuroimaging workflow by bringing brain imaging to the patient’s bedside. For more information, visit [hyperfine.io](https://hyperfine.io).

Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240228281785/en/): <https://www.businesswire.com/news/home/20240228281785/en/>

### **Investor Contact**

Marissa Bych  
Gilmartin Group LLC  
[marissa@gilmartinir.com](mailto:marissa@gilmartinir.com)

Source: Hyperfine, Inc.